Combined risk allele score of eight type 2 diabetes genes is associated with reduced first-phase glucose-stimulated insulin secretion during hyperglycemic clamps

Diabetes

Volumn 59, Issue 1, 2010, Pages 287-292

  'T Hart, Leen M ^a   Simonis Bik, Annemarie M ^b   Nijpels, Giel ^b   Van Haeften, Timon W ^c   Schäfer, Silke A ^d   Houwing Duistermaat, Jeanine J ^a   Boomsma, Dorret I ^e   Groenewoud, Marlous J ^a   Reiling, Erwin ^a   Van Hove, Els C ^a   Diamant, Michaela ^b   Kramer, Mark H H ^b   Heine, Robert J ^b,f   Maassen, J Antonie ^a,b   Kirchhoff, Kerstin ^d   Machicao, Fausto ^d   Häring, Hans Ulrich ^d   Slagboom, P Eline ^a   Willemsen, Gonneke ^e   Eekhoff, Elisabeth M ^b   De Geus, Eco J ^e   Dekker, Jacqueline M ^b   Fritsche, Andreas ^d   more..

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e VU UNIVERSITY AMSTERDAM   (Netherlands)

^f ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; TRANSCRIPTION FACTOR 7 LIKE 2; INSULIN;

ADULT; ALLELE; ARTICLE; B LYMPHOCYTE; CDKAL1 GENE; FEMALE; FOLLOW UP; GENE; GENE LOCUS; GENOTYPE; HHEX GENE; HUMAN; HYPERGLYCEMIA; IFG2BP2 GENE; INSULIN RELEASE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MTNR1B GENE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET CELL TUMOR; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SLC30A8 GENE; AGED; BLOOD; BODY MASS; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; GENETICS; GERMANY; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INTOLERANCE; MIDDLE AGED; MULTICENTER STUDY; NETHERLANDS; REFERENCE VALUE; RISK ASSESSMENT; RISK FACTOR; SECRETION;

ADULT; AGED; ALLELES; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; GENOTYPE; GERMANY; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INTOLERANCE; HUMANS; HYPERGLYCEMIA; INSULIN; MALE; MIDDLE AGED; NETHERLANDS; POLYMORPHISM, SINGLE NUCLEOTIDE; REFERENCE VALUES; RISK ASSESSMENT; RISK FACTORS;

EID: 77449161166     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db09-0736     Document Type: Article

References (40)

1. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, Boutin P, Vincent D, Belisle A, Hadjadj S, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007;445:881-885
2. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, Roix JJ, Kathiresan S, Hirschhorn JN, Daly MJ, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007;316:1331-1336
3. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, Erdos MR, Stringham HM, Chines PS, Jackson AU, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007;316:1341-1345
4. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, Timpson NJ, Perry JR, Rayner NW, Freathy RM, et al. Replication of genome-wide association signals in U.K. samples reveals risk loci for type 2 diabetes. Science 2007;316:1336-1341 (Pubitemid 46871654)
5. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T, de Bakker PI, Abecasis GR, Almgren P, Andersen G, et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 2008;40:638-645
6. Weedon MN, Mccarthy MI, Hitman G, Walker M, Groves CJ, Zeggini E, Rayner NW, Shields B, Owen KR, Hattersley AT, Frayling TM. Combining information from common type 2 diabetes risk polymorphisms improves disease prediction. PLoS Med 2006;3:e374
7. Cauchi S, Meyre D, Durand E, Proenca C, Marre M, Hadjadj S, Choquet H, De GF, Gaget S, Allegaert F, et al. Post genome-wide association studies of novel genes associated with type 2 diabetes show gene-gene interaction and high predictive value. PLoS ONE 2008;3:e2031
8. Lango H, Palmer CN, Morris AD, Zeggini E, Hattersley AT, Mccarthy MI, Frayling TM, Weedon MN. Assessing the combined impact of 18 common genetic variants of modest effect sizes on type 2 diabetes risk. Diabetes 2008;57:3129-3135
9. Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, Berglund G, Altshuler D, Nilsson P, Groop L. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 2008;359:2220-2232
10. Pascoe L, Frayling TM, Weedon MN, Mari A, Tura A, Ferrannini E, Walker M. Beta cell glucose sensitivity is decreased by 39% in non-diabetic individuals carrying multiple diabetes-risk alleles compared with those with no risk alleles. Diabetologia 2008;51:1989-1992
11. Haupt A, Staiger H, Schafer SA, Kirchhoff K, Guthoff M, Machicao F, Gallwitz B, Stefan N, Haring HU, Fritsche A. The risk allele load accelerates the age-dependent decline in beta cell function. Diabetologia 2009;52:457-462
12. Haupt A, Guthoff M, Schafer SA, Kirchhoff K, Machicao F, Gallwitz B, Staiger H, Stefan N, Fritsche A, Haring HU. The inhibitory association of recent type 2 diabetes risk loci on insulin secretion is modulated by insulin sensitivity. J Clin Endocrinol Metab 2009;94:1775-1780
13. Stančáková A, Kuulasmaa T, Paananen J, Jackson AU, Bonnycastle LL, Collins FS, Boehnke M, Kuusisto J, Laakso M. Association of 18 confirmed susceptibility loci for type 2 diabetes with indices of insulin release, proinsulin conversion, and insulin sensitivity in 5,327 nondiabetic Finnish men. Diabetes 2009;58:2129-2136
14. Simonis-Bik AM, Eekhoff EM, de Moor MH, Kramer MH, Boomsma DI, Heine RJ, Dekker JM, Maassen JA, 't Hart LM, Diamant M, de Geus EJ. Genetic influences on the insulin response of the beta cell to different secretagogues. Diabetologia 2009;52:2570-2577
15. Tschritter O, Stumvoll M, Machicao F, Holzwarth M, Weisser M, Maerker E, Teigeler A, Haring H, Fritsche A. The prevalent Glu23Lys polymorphism in the potassium inward rectifier 6.2 (KIR6.2) gene is associated with impaired glucagon suppression in response to hyperglycemia. Diabetes 2002;51:2854-2860
16. 't Hart LM, Van Haeften TW, Dekker JM, Bot M, Heine RJ, Maassen JA. Variations in insulin secretion in carriers of the E23K variant in the KIR6.2 subunit of the ATP-sensitive K(+) channel in the β-cell. Diabetes 2002;51:3135-3138
17. Schafer SA, Tschritter O, Machicao F, Thamer C, Stefan N, Gallwitz B, Holst JJ, Dekker JM, 't Hart LM, Nijpels G, et al. Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 2007;50:2443-2450
18. Groenewoud MJ, Dekker JM, Fritsche A, Reiling E, Nijpels G, Heine RJ, Maassen JA, Machicao F, Schafer SA, Haring HU, et al. Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps. Diabetologia 2008;51:1659-1663
19. Florez JC. Newly identified loci highlight beta cell dysfunction as a key cause of type 2 diabetes: where are the insulin resistance genes? Diabetologia 2008;51:1100-1110
20. Perry JR, Frayling TM. New gene variants alter type 2 diabetes risk predominantly through reduced beta-cell function. Curr Opin Clin Nutr Metab Care 2008;11:371-377
21. Defronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223
22. Fritsche A, Stefan N, Hardt E, Schutzenauer S, Haring H, Stumvoll M. A novel hyperglycaemic clamp for characterization of islet function in humans: assessment of three different secretagogues, maximal insulin response and reproducibility. Eur J Clin Invest 2000;30:411-418
23. Simonis-Bik AM, Eekhoff EM, Diamant M, Boomsma DI, Heine RJ, Dekker JM, Willemsen G, van Leeuwen M, de Geus EJ. The heritability of HbA1c and fasting blood glucose in different measurement settings. Twin Res Hum Genet 2008;11:597-602
24. Ruige JB, Dekker JM, Nijpels G, Poppsnijders C, Stehouwer CDA, Kostense PJ, Bouter LM, Heine RJ. Hyperproinsulinaemia in impaired glucose tolerance is associated with a delayed insulin response to glucose. Diabetologia 1999;42:177-180
25. Van Haeften TW, Zonderland ML, Dubbeldam S, Erkelens DW. Insulin secretion in normal glucose-tolerant relatives of type 2 diabetic subjects: assessments using hyperglycemic glucose clamps and oral glucose tolerance tests. Diabetes Care 1998;21:278-282
26. Fritsche A, Stefan N, Hardt E, Haring H, Stumvoll M. Characterisation of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion. Diabetologia 2000;43:852-858
27. Nijpels G, Boorsma W, Dekker JM, Hoeksema F, Kostense PJ, Bouter LM, Heine RJ. Absence of an acute insulin response predicts onset of type 2 diabetes in a Caucasian population with impaired glucose tolerance. J Clin Endocrinol Metab 2008;93:2633-2638
28. Mitrakou A, Vuorinen-Markkola H, Raptis G, Toft I, Mokan M, Strumph P, Pimenta W, Veneman T, Jenssen T, Bolli G, et al. Simultaneous assessment of insulin secretion and insulin sensitivity using a hyperglycemic clamp. J Clin Endocrinol Metab 1992;75:379-382
29. Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and B-cell glucose sensitivity from the response to intraveneous glucose. J Clin Invest 1981;68:1456-1467
30. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP, et al. Quantification of the relationship between insulin sensitivity and beta cell function in human subjects: evidence for a hyperbolic function. Diabetes 1993;42:1663-1672
31. Staiger H, Machicao F, Schafer SA, Kirchhoff K, Kantartzis K, Guthoff M, Silbernagel G, Stefan N, Haring HU, Fritsche A. Polymorphisms within the novel type 2 diabetes risk locus MTNR1B determine beta-cell function. PLoS ONE 2008;3:e3962
32. Prokopenko I, Langenberg C, Florez JC, Saxena R, Soranzo N, Thorleifsson G, Loos RJ, Manning AK, Jackson AU, Aulchenko Y, et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet 2009;41:77-81
33. Lyssenko V, Nagorny CL, Erdos MR, Wierup N, Jonsson A, Spegel P, Bugliani M, Saxena R, Fex M, Pulizzi N, et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet 2009;41:82-88
34. Bouatia-Naji N, Bonnefond A, Cavalcanti-Proenca C, Sparso T, Holmkvist J, Marchand M, Delplanque J, Lobbens S, Rocheleau G, Durand E, et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet 2009;41:89-94
35. Lyssenko V, Almgren P, Anevski D, Perfekt R, Lahti K, Nissen M, Isomaa B, Forsen B, Homstrom N, Saloranta C, et al. Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes 2005;54:166-174
36. Chimienti F, Devergnas S, Favier A, Seve M. Identification and cloning of a beta-cell-specific zinc transporter, ZnT-8, localized into insulin secretory granules. Diabetes 2004;53:2330-2337
37. da Silva X, Loder MK, McDonald A, Tarasov AI, Carzaniga R, Kronenberger K, Barg S, Rutter GA. TCF7L2 regulates late events in insulin secretion from pancreatic islet β-cells. Diabetes 2009;58:894-905
38. Lyssenko V, Lupi R, Marchetti P, Del GS, Orho-Melander M, Almgren P, Sjogren M, Ling C, Eriksson KF, Lethagen AL, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 2007;117:2155-2163
39. Mccarthy MI, Hattersley AT. Learning from molecular genetics: novel insights arising from the definition of genes for monogenic and type 2 diabetes. Diabetes 2008;57:2889-2898
40. Ridderstrale M, Groop L. Genetic dissection of type 2 diabetes. Mol Cell Endocrinol 2009;297:10-17